Novo Nordisk Bet Everything on a Pill Beating Lilly's Shot

Novo Nordisk finally built a pill to answer Eli Lilly's injectable dominance. This week's earnings were supposed to prove the comeback was real. Instead, investors got a pointed reminder of exactly who's still winning this fight.